Utilization of allopurinol in the Australian community

Internal Medicine Journal

Volumn 38, Issue 6 A, 2008, Pages 388-395

  Chung, Y ^a,b   Lu, C Y ^a,b,d   Graham, G G ^a,b   Mant, A ^a,c   Day, R O ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allopurinol; Australia; Drug utilization; Gout suppressant administration and dosage

Indexed keywords

ALLOPURINOL; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; SULFINPYRAZONE;

ARTICLE; AUSTRALIA; COMMUNITY CARE; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG UTILIZATION; EDUCATION PROGRAM; GEOGRAPHIC DISTRIBUTION; GOUT; HUMAN; HYPERURICEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MEDICARE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

ALLOPURINOL; AUSTRALIA; COMMUNITY HEALTH SERVICES; DRUG UTILIZATION; GOUT; GOUT SUPPRESSANTS; GUIDELINE ADHERENCE; HUMANS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 45749091356     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01641.x     Document Type: Article

References (38)

1. Arromdee A, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002 29 : 2403 6.
2. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004 31 : 1582 7.
3. Zeng Q, Wang Q, Chen R, Xiao Z, Huang S, Xu J. Primary gout in Shantou: a clinical and epidemiological study. Chin Med J (Engl) 2003 116 : 66 9.
4. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006 54 : 2688 96.
5. Johnson RJ, Rideout BA. Uric acid and diet - insights into the epidemic of cardiovascular disease. N Engl J Med 2004 350 : 1071 3.
6. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? Am J Med 2005 118 : 816 26.
7. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 2005 64 : 267 72.
8. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984 76 : 47 56.
9. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006 81 : 925 34.
10. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005 44 : 1038 42.
11. Therapeutic Guidelines Ltd. Gout: management revised Nov 2007]. eTG complete [Internet Melbourne : Therapeutic Guidelines Limited 2007 Rheumatology 2007 cited 2007 Dec 16 Available from URL : http://www.tg.com.au/ip/complete/
12. Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988 26 : 423 8.
13. Peterson GM, Boyle RR, Francis HW, Oliver NW, Paterson J, von Witt RJ et al. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 1990 39 : 419 21.
14. Pascual E, Sivera F. Therapeutic advances in gout. Curr Opin Rheumatol 2007 19 : 122 7.
15. Schlesinger N, Moore DF, Sun JD, Schumacher HR Jr. A survey of current evaluation and treatment of gout. J Rheumatol 2006 33 : 2050 52.
16. Smith P, Karlson N, Balakrishnan RN. Quality use of allopurinol in the elderly. J Qual Clin Pract 2000 20 : 42 3.
17. Bellamy N, Brooks PM, Emmerson BT, Gilbert JR, Campbell J, McCredie M. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989 151 : 531 7.
18. Medicare Australia. Pharmaceutical Benefits Scheme Statistical Reports for Items 1227N, 1940D, 2094F, 2600W, 2601X, 2603B, 2604C, January 1992 to December 2005. [cited 2006 Nov 29]. Available from URL : http://www. medicareaustralia.gov.au/statistics/dyn_pbs/forms/pbs_tab1.shtml
19. Commonwealth Department of Health and Ageing. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. 2006 Apr cited 2006 Nov 29]. Available from URL : http://www.pbs.gov.au/html/healthpro/publication/ view?date=20060401&type=FlashPaper&name=general-schedule
20. Commonwealth Department of Health and Ageing. Australian Statistics on Medicines 2003 cited Nov 29]. Available from URL : http://www.health.gov.au/ internet/wcms/publishing.nsf/Content/pbs-pubs-asm2003/
21. World Health Organization. Guidelines for ATC Classification and DDD Assignment, 7th edn. Oslo : WHO Collaborating Centre for Drug Statistics Methodology 2004.
22. Terkeltaub RA. Gout. N Engl J Med 2003 349 : 1647 55.
23. Schepers GW. Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid. J Int Med Res 1981 9 : 511 15.
24. Australian Bureau of Statistics (ABS). Population estimates by age and sex, Northern Territory by geographic classification - electronic delivery. Canberra : ABS. 2005 Jun. ABS Cat. No.: 3235.7.55.001.
25. Australian Bureau of Statistics (ABS). Population estimates by age and sex, New South Wales by geographic classification - electronic delivery. Canberra : ABS. 2005 Jun. ABS Cat. No.: 3235.1.55.001.
26. Australian Bureau of Statistics (ABS). Population estimates by age and sex, Tasmania by geographic classification - electronic delivery. Canberra : ABS. 2005 Jun. ABS Cat. No.: 3235.6.55.001.
27. Byron P, Yuejen Z, Guthridge S, Brailsford R, Stacey F, Parkinson J. Medicare and Pharmaceutical Benefits Scheme Usage Patterns in the Northern Territory 1993/94 to 2003/04. Northern Territory : Department of Health and Community Services, Darwin 2005.
28. Australian Bureau of Statistics (ABS). Regional statistics, Northern Territory - electronic delivery. Canberra : ABS. 2006 Dec. ABS Cat. No.: 1362.7.
29. Emmerson BT, Douglas W, Doherty RL, Feigl P. Serum urate concentrations in the Australian Aboriginal. Ann Rheum Dis 1969 28 : 150 56.
30. Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian Aboriginal community in North Queensland, Australia. A WHO-ILAR COPCORD survey. J Rheumatol 2004 31 : 965 72.
31. Peterson GM, Sugden JE. Educational program to improve the dosage prescribing of allopurinol. Med J Aust 1995 162 : 74 7.
32. eAMH. Australian Medicines Handbook 2007 Drugs for Gout: Allopurinol (Section 15.3) 2007 Jul cited 2007 Dec 16 627 8.
33. Emmerson BT. The management of gout. N Engl J Med 1996 334 : 445 51.
34. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993 27 : 337 43.
35. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005 102 : 4134 9.
36. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006 33 : 1646 50.
37. Vazquez-Mellado J, Morales E, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001 60 : 981 3.
38. Kelman CW, Pearson SA, Day RO, Holman CD, Kliewer EV, Henry DA. Evaluating medicines: let's use all the evidence. Med J Aust 2007 186 : 249 52.